Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  News  >  Companies  >  All News

News : Companies
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance ProfessionalsCalendarSectors

Citius Pharmaceuticals : CTXR Presentation_Winter 2019

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/12/2019 | 01:02pm EDT

Citius Pharmaceuticals, Inc.

Corporate Presentation

Winter 2019

NASDAQ: CTXR

Citius Management Team (Leadership)

Leonard Mazur, Director and Chairman of the Board

Mr. Mazur is a highly accomplished entrepreneur and pharmaceutical industry executive with notable accomplishments in founding, building and creating value and returns for the investors. He has been instrumental in launching many brands which have been at the forefront in their respective categories. Mr. Mazur is a founder/co-founder of the following companies: Genesis, Triax, Akrimax, and Rouses Point Pharmaceuticals. He has previously served in Executive Management positions at Medicis Pharmaceuticals, ICN Pharmaceuticals, Knoll Pharma (divison of BASF) and Cooper Laboratories. Mr. Mazur is a member of the Board of Trustees of Manor College and is a recipient of the Ellis Island Medal of Honor. Mr. Mazur received both his BA and MBA from Temple University and has served in the U.S. Marine Corps Reserves.

Myron Holubiak, President & CEO and Director

Mr. Holubiak has extensive experience in managing and leading both large and emerging pharmaceutical and life sciences companies. He is Co-founder, Director and CEO of Leonard Meron Biosciences, Inc., and served as CEO until the merger with Citius Pharmaceuticals, Inc. in March 2016, and then assuming the CEO role for the merged entity, Citius Pharmaceuticals, Inc.. He is the former President of Roche Laboratories, Inc., a major research based pharmaceutical company. During his tenure as President of Roche, Holubiak transformed Roche Labs into a leading antibiotic and biotechnology company. He was also founder of Emron, Inc., a pioneering health economics and managed care consulting company, and helped to create the Academy of Managed Care Pharmacy (AMCP). He is a former director and past Chairman of Bioscrip, Inc., a national home infusion services provider. He is currently a director of bioAffinity, Inc., and Assembly Biosciences, Inc. He received a BS in the double majors of Molecular Biology and Biophysics with post-graduate work in Biophysics from the U of Pittsburgh; he received advanced business training from the Harvard Business School, the Amos Tuck School at Dartmouth, and the University of London; and, advanced training in health economics from the University of York's Centre for Health Economics.

CTXR

2

Disclaimer

This presentation has been prepared by Citius Pharmaceuticals, Inc. (the "Company") for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the Company or any director, employee, agent, or adviser of the Company. This presentation does not purport to be all-inclusive or to contain all of the information you may desire. The information contained in this presentation and the comments and remarks of the representatives of the Company made during the presentation to which this presentation relates are integrally related and, as such, are intended to be delivered and understood together. Information provided in this presentation speaks only as of the date hereof. The Company assumes no obligation to update any statement after the date of this presentation as a result of new information, subsequent events or any other circumstances.

This presentation also includes express and implied forward-looking statements regarding the current expectations, estimates, opinions and beliefs of the Company that are not historical facts. Such forward-looking statements may be identified by words such as "believes", "expects", "endeavors", "anticipates", "intends", "plans", "estimates", "projects", "should" "objective" and variations of such words and similar words. The accuracy of such statements is dependent upon future events, and involves known and unknown risks, uncertainties and other factors beyond

the Company's control that may cause actual results to differ materially from what is presented herein. Investors are strongly encouraged to

carefully review the Company's SEC filings for a listing of the risks that could cause actual results to differ from these forward looking statements. These forward-looking statements speak only as of the date of this presentation and should not be construed as statements of facts.

CTXR

3

Investment Opportunity

Olympic Motto: "Citius, Altius, Fortius" (Faster, Higher, Stronger)

  • Low Risk/ High Reward Strategy
    • Low development risk … focused on 505(b)2 regulatory pathway products,
      • avoids unnecessary duplication of studies already performed on previously approved drugs
      • results in a much less expensive and much faster route to approval, compared with a traditional development path [such as 505(b)(1)], while creating new, differentiated products with high commercial value expected.
    • Unique indications…little or no competition…similar to an NCE in market potential
  • Successful management team with extensive experience
    • Approximately $24 million invested privately by founders and $16.5 million by the public
  • Partnership with MD Anderson Cancer Center for Cancer and Infectious Disease
  • Multiple near-term milestones and catalysts

CTXR

4

Unique Pipeline in Progressive Stages

  • Phase 3: Mino-Lok®
    • Lead product (Mino-Lok) is a unique antibiotic lock therapy that salvages central lines in bacteremic patients. This is a very serious problem with a clear unmet medical need. We estimate the market to be >$1 billion worldwide.
  • Phase 2: CITI-002(Halo-Lido)
    • Hydrocortisone/lidocaine completed Phase 2a. New formulation (with halobetasol) requires animal tox study prior to phase 2b trial. Would be the only FDA approved Rxtherapy for hemorrhoids. We estimate the market to be >$1 billion in US.
  • Pre-Clinical:CITI-101(Mino-Wrap)
    • Unique product that prevents infections associated with breast implants. Preclinical data suggest prolonged protection against colonization by key organisms during time when most susceptible. We estimate the market to be ~$200 million in US ($400 million worldwide).
  • Targeted Acquisitions
    • Business development activity focused on 505(b)2 products with unique indications.

CTXR

5

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Citius Pharmaceuticals Inc. published this content on 12 September 2019 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 12 September 2019 17:01:02 UTC

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news "Companies"
06:47aCSTONE PHARMACEUTICALS : Voluntary announcement - cstone announces preliminary results from phase i trial of cs1002 demonstrating characteristics comparable to ipilimumab
PU
06:42aCSTONE PHARMACEUTICALS : Voluntary announcement - cstone announces promising orr, anti-tumor activity and safety data with its anti-pd-l1 antibody cs1001 in msi-h/dmmr solid tumors
PU
06:32aVCREDIT : Interim Report 2019
PU
06:32aEVERGREEN PRODUCTS : Connected transaction issue of new shares to a connected person under specific mandate
PU
06:27aEVERGREEN PRODUCTS : Placing of existing shares and top-up subscription of new shares
PU
06:22aCHINA SAITE : Inside information
PU
06:22aYESTAR HEALTHCARE : Next Day Disclosure Returns
PU
06:17aORIENTAL WEAVERS : Introduces new alternatives to chinese rug imports for ny buyers
PU
06:17aSINO I TECHNOLOGY : List of Directors and their Role and Function
PU
06:12aQILU EXPRESSWAY : (1) proposed re-election and election of directors; (2) proposed re-election and election of supervisors; and (3) closure period of register of members
PU
Latest news "Companies"